— Clovis Oncology (NASDAQ: CLVS) reported a fourth-quarter 2019 loss of $1.81 per share versus a loss of $1.71 per share expected.
— Product revenues grew by 30% to $39.3 million versus $38.97 million expected. The top line was driven by an increase in the US net product revenue.
— The supply of free drugs distributed to eligible patients in the U.S. through the Rubraca patient assistance program for Q4 2019 was 18% of the overall US commercial supply, compared to 26% reported in Q4 2018.
— Research and development expenses increased by 2% year-over-year due primarily to higher research and development costs for rucaparib clinical trials.
— The company believes it has sufficient cash, cash equivalents, and available-for-sale securities to fund its operating plan into the second half of 2021. This is based on anticipated revenue, spending, available financing sources, and existing cash.
We’re on Flipboard! Follow us to receive the latest stock market, earnings, and financial news at your fingertips
DG Earnings: All you need to know about Dollar General’s Q1 2023 earnings results
Dollar General Corporation (NYSE: DG) reported its first quarter 2023 earnings results today. Net sales increased 6.8% year-over-year to $9.3 billion, driven mainly by positive sales contributions from new stores and
HRL Earnings: Key highlights from Hormel Foods’ Q2 2023 financial results
Hormel Foods Corporation (NYSE: HRL) reported second quarter 2023 earnings results today. Net sales of $3 billion were down 3.8% year-over-year. Net earnings attributable to Hormel Foods Corporation were $217.2
Everything you need to know about Salesforce’s Q1 2024 financial results
Customer relationship management platform Salesforce, Inc. (NYSE: CRM) on Wednesday reported an increase in first-quarter adjusted earnings, aided by strong revenue growth. First-quarter profit, excluding non-recurring items, increased to $1.69